1832 Asset Management
BCRX icon

1832 Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

1832 Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,978
Closed -$7K – 678
2019
Q4 		$7K Buy
+1,978
New +$4.98K ﹤0.01% 621

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

1832 Asset Management's BCRX Position: Q1 2020 in Review

1832 Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2020, closing a stake of 1,978 shares — an estimated $7K sold.

1832 Asset Management first reported a position in BCRX in Q4 2019 and held it in 1 quarter. The position peaked at $7K in Q4 2019. 134 funds tracked by Wall St. Rank hold BCRX as of Q1 2020.

  • 1832 Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • 1832 Asset Management sold 1,978 BioCryst Pharmaceuticals shares in Q1 2020, an estimated $7K.
  • 1832 Asset Management first reported a position in BioCryst Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • 1832 Asset Management's BioCryst Pharmaceuticals position peaked at $7K in Q4 2019.
  • 134 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2020.

Based on 1832 Asset Management's 13F filing for Q1 2020, filed 14 May 2020.